Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CEO Jeremy Bender sold 16,058 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.77, for a total value of $108,712.66. Following the completion of the transaction, the chief executive officer directly owned 161,365 shares of the company's stock, valued at $1,092,441.05. This represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Day One Biopharmaceuticals Stock Performance
Shares of DAWN stock traded up $0.01 during mid-day trading on Tuesday, hitting $6.82. The company's stock had a trading volume of 1,763,028 shares, compared to its average volume of 2,153,315. The company has a market cap of $698.57 million, a PE ratio of -7.18 and a beta of -1.26. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $16.76. The company's fifty day simple moving average is $6.61 and its 200-day simple moving average is $7.71.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $33.91 million during the quarter, compared to analyst estimates of $35.55 million. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%. On average, equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of DAWN. Hudson Bay Capital Management LP lifted its holdings in Day One Biopharmaceuticals by 12.7% during the second quarter. Hudson Bay Capital Management LP now owns 1,296,700 shares of the company's stock valued at $8,429,000 after purchasing an additional 146,300 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Day One Biopharmaceuticals by 15.5% during the 2nd quarter. Vestal Point Capital LP now owns 3,000,000 shares of the company's stock worth $19,500,000 after buying an additional 401,873 shares in the last quarter. Man Group plc increased its holdings in Day One Biopharmaceuticals by 46.1% in the second quarter. Man Group plc now owns 56,862 shares of the company's stock worth $370,000 after buying an additional 17,950 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $89,000. Finally, Bayesian Capital Management LP raised its stake in Day One Biopharmaceuticals by 56.1% during the 2nd quarter. Bayesian Capital Management LP now owns 28,100 shares of the company's stock worth $183,000 after buying an additional 10,100 shares during the period. Institutional investors own 87.95% of the company's stock.
Analysts Set New Price Targets
DAWN has been the subject of a number of research reports. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Wedbush reissued an "outperform" rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Finally, Piper Sandler initiated coverage on shares of Day One Biopharmaceuticals in a research report on Monday. They set an "overweight" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and an average price target of $25.29.
Get Our Latest Stock Report on DAWN
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access